(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
-0.35% £ 1 435.00
Live Chart Being Loaded With Signals
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders...
Stats | |
---|---|
Dagens volum | 355 661 |
Gjennomsnittsvolum | 508 618 |
Markedsverdi | 1.95B |
EPS | £0 ( 2024-04-24 ) |
Neste inntjeningsdato | ( £0 ) 2024-07-25 |
Last Dividend | £36.50 ( 2016-06-16 ) |
Next Dividend | £0 ( N/A ) |
P/E | 1 435.00 |
ATR14 | £1.329 (0.09%) |
Volum Korrelasjon
Indivior PLC Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Indivior PLC Korrelasjon - Valuta/Råvare
Indivior PLC Økonomi
Annual | 2023 |
Omsetning: | £1.09B |
Bruttogevinst: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2023 |
Omsetning: | £1.09B |
Bruttogevinst: | £907.00M (82.98 %) |
EPS: | £0.0100 |
FY | 2022 |
Omsetning: | £901.00M |
Bruttogevinst: | £742.00M (82.35 %) |
EPS: | £-0.380 |
FY | 2021 |
Omsetning: | £791.00M |
Bruttogevinst: | £664.00M (83.94 %) |
EPS: | £1.410 |
Financial Reports:
No articles found.
Indivior PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
First Dividend | £10.40 | 2015-09-17 |
Last Dividend | £36.50 | 2016-06-16 |
Next Dividend | £0 | N/A |
Payout Date | 2016-07-29 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | £46.90 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.12 | -- |
Div. Sustainability Score | 4.95 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 1.992 | -- |
Year | Amount | Yield |
---|---|---|
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £0 | 0.00% |
2019 | £0 | 0.00% |
2020 | £0 | 0.00% |
2021 | £0 | 0.00% |
2022 | £0 | 0.00% |
2023 | £0 | 0.00% |
2024 | £0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
AEP.L | Dividend Knight | 2023-09-07 | Annually | 32 | 1.20% | |
TLY.L | Dividend Junior | 2023-09-07 | Semi-Annually | 5 | 1.72% | |
LMS.L | Dividend King | 2023-08-10 | Semi-Annually | 6 | 129.95% | |
CMCL.L | Dividend Knight | 2023-07-13 | Quarterly | 12 | 3.19% | |
RLE.L | Dividend Knight | 2023-07-06 | Quarterly | 13 | 4.33% | |
HEAD.L | Dividend Knight | 2023-10-26 | Semi-Annually | 32 | 2.61% | |
ASLI.L | Dividend Knight | 2023-08-31 | Quarterly | 7 | 3.13% | |
UTL.L | Dividend Knight | 2023-09-28 | Quarterly | 21 | 2.08% | |
MNG.L | Dividend King | 2023-09-28 | Semi-Annually | 5 | 5.17% | |
DCC.L | Dividend King | 2023-05-25 | Semi-Annually | 25 | 1.96% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00183 | 1.500 | 9.96 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00102 | 1.200 | 9.97 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00542 | 1.500 | -1.051 | -1.576 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0.968 | 0.800 | -0.161 | -0.129 | [1 - 3] |
quickRatioTTM | 0.526 | 0.800 | -1.609 | -1.287 | [0.8 - 2.5] |
cashRatioTTM | 0.242 | 1.500 | 9.77 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.144 | -1.500 | 7.59 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0.553 | 1.000 | -0.906 | -0.906 | [3 - 30] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -1.339 | -2.68 | [0 - 20] |
debtEquityRatioTTM | 0.215 | -1.500 | 9.14 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.830 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0192 | 1.000 | -1.616 | -1.616 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -1.117 | 1.000 | -7.32 | -7.32 | [0.2 - 2] |
assetTurnoverTTM | 0.559 | 0.800 | 9.60 | 7.68 | [0.5 - 2] |
Total Score | 4.95 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 1 237.27 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00542 | 2.50 | -0.676 | -1.576 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.68 | 2.00 | -0.892 | -2.68 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -2.29 | 2.00 | -0.764 | -1.528 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -0.288 | 1.000 | -9.70 | 0 | [0.1 - 0.5] |
Total Score | -0.971 |
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.